Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Igc Pharma Inc (NY: IGC )

0.3525 +0.0192 (+5.76%)
Official Closing Price Updated: 6:30 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 172,978
Open 0.3339
Bid (Size) 0.3449 (10)
Ask (Size) 0.3520 (3)
Prev. Close 0.3333
Today's Range 0.3302 - 0.3588
52wk Range 0.2501 - 0.9099
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
Via ACCESSWIRE
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
Via ACCESSWIRE

Performance

YTD
+27.72%
+27.72%
1 Month
-14.25%
-14.25%
3 Month
-6.08%
-6.08%
6 Month
-28.06%
-28.06%
1 Year
+10.50%
+10.50%

More News

Read More
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
Via ACCESSWIRE
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Receives Two Awards in NIH’s AI PREPARE Challenge
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
Via ACCESSWIRE
IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
Via PRLog
Topics Artificial Intelligence Intellectual Property Regulatory Compliance
Exposures Artificial Intelligence Intellectual Property Legal
The Analyst Verdict: IGC Pharma In The Eyes Of 4 Experts
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing IGC-AD1’s Potential to Effectively Target Tau Pathology, Improve Cognitive Function in Alzheimer’s
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Advances IGC-AD1 Research to Potentially Deliver ‘Breakthrough Treatment’ in Alzheimer’s Disease
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property Product Safety
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
From IGC Pharma, Inc.
Via Business Wire
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual Meeting
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property Regulatory Compliance
Exposures Artificial Intelligence Intellectual Property Legal
IGC Announces Results of its 2024 Annual Stockholders Meeting
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Preclinical Research Evaluating New Molecule IGC-1C in Treatment of Alzheimer’s Disease
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc.’s (NYSE American: IGC) AI-Driven Approach Reveals ‘Promising Opportunity’ for IGC-1A to Be a Potential GLP-1 Agonist
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist
From IGC Pharma
Via Business Wire
IGC Stock Earnings: IGC Pharma Beats EPS, Misses Revenue for Q1 2025
Via InvestorPlace
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2025 Financial, Operational Results Report
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
IGC Pharma Revenue Declines 51% YoY Due To Completion Of Its Legacy Project In India, Highlights Important Milestones In Alzheimer's Research
Via Benzinga
IGC Pharma Reports First Quarter Fiscal 2025 Results
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives ‘Buy’ Recommendation in AGP’s Analyst Coverage Research Report
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
From IGC Pharma, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.